FDA Cleared the First Lutathera Copy. The Hot Lab Is the Real Trial
Curium’s Bexlutry is the first 505(b)(2) radioligand equivalent. The regulatory shortcut is done. Hospital clocks, isotope supply, and a pending $8 billion merger now decide whether Novartis’s NET franchise actually erodes.
On September 14, 2026, the FDA approved Curium Pharma’s New Drug Application for Bexlutry (lutetium Lu 177 dotatate injection) in adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, covering foregut, midgut, and hindgut disease. The product is the first radioligand equivalent cleared through the 505(b)(2) pathway, relying on physicochemical and targeted bridging data rather than a new standalone efficacy trial.
For years, investors treated lutetium-177 therapies as almost uncopyable. The isotope decays with a 6.7-day half-life, forcing just-in-time synthesis, specialized hot-lab handling, and institutional site certification. Curium has demonstrated that regulators will accept a radiotherapeutic copy built on someone else’s clinical dossier. What remains unproven is whether hospitals will trust a second supplier with a drug that cannot sit on a shelf.
A borrowed file and a skinny adult label
Bexlutry’s clinical dossier is borrowed. The application leans on published results from Novartis’s Phase 3 NETTER-1 trial and the ERASMUS expanded-access study, the exact clinical foundation that underwrote Lutathera’s approval. The approved regimen delivers a cumulative 29.6 GBq across four 7.4 GBq infusions every eight weeks, co-administered with amino acid infusions to limit renal toxicity.
The label is intentionally restricted. Because Lutathera still holds FDA pediatric exclusivity, Curium’s product enters through a pediatric carve-out restricted strictly to adults. That skinny label represents the classic 505(b)(2) commercial trade-off: capture the high-volume adult GEP-NET market immediately, while ceding pediatric niches to the reference drug.
The approval does not create a complete Lutathera twin, but rather an adult alternative entering a clinical landscape Novartis spent years building. That prior familiarity eases adoption, yet also forces Curium to compete directly inside ordering and billing channels established by the incumbent.
An $816 million franchise built on more than patents
For Novartis, adult neuroendocrine tumors represent an established commercial engine. Lutathera generated $816 million in global net sales in 2025, up 13 percent year over year, and contributed another $436 million through the first half of 2026. Those returns reflect nearly a decade of strategic capital allocation. Novartis committed $3.9 billion to acquire Advanced Accelerator Applications in 2017 to secure Lutathera, followed by $2.1 billion for Endocyte in 2018 to acquire Pluvicto. The Swiss pharma giant did not simply buy patents; it built dedicated manufacturing suites, secure isotope pipelines, and specialized hospital delivery channels capable of coordinating radioactive doses on strict calendars.
Curium moved aggressively to clear the legal runway. When Novartis filed patent infringement litigation to block market entry, a Delaware federal district court invalidated the asserted patent claims in June 2026. While Novartis is appealing, the ruling eliminated the injunction barrier.
Curium brings substantial industrial scale to the launch. The specialist operates four manufacturing sites across 70 countries with 3,800 employees. In August 2026, Curium signed a definitive agreement to acquire Lantheus for up to $8 billion, targeting completion in early 2027 to forge a combined radiopharma company generating roughly $2.1 billion in annual revenue. A copy from an unproven supplier might easily be sidelined, but Curium’s infrastructure establishes a fully capitalized second supply chain.
The copycat test moves from FDA to Friday infusions
The prevailing industry thesis held that conventional generic competition could not match radiopharma logistics. Unlike small molecules, lutetium-177 cannot be stockpiled. It requires active nuclear reactors, specialized radiochemical processing, and certified clinical suites ready for immediate infusion before the payload decays.
Bexlutry proves the regulatory moat can be crossed without running a redundant Phase 3 study. Now the commercial test begins. Long-term hospital purchasing agreements, delivery punctuality, isotope access, and institutional pricing will determine whether Lutathera’s $816 million revenue stream erodes or holds. In radioactive oncology, an equivalent that misses an infusion window is clinically unusable.
Reliability will govern uptake before price concessions take effect. Neuroendocrine tumor clinics schedule patient cycles weeks in advance. A missed batch represents a cancelled treatment and an upset patient while the isotope decays in transit. Cancer centers will not change vendors solely on cost; they will demand proof that Curium can match Novartis on delivery precision before negotiating discounts.
Novartis preserves pediatric exclusivity, entrenched hospital relationships, and an ongoing appeal. Curium counters with regulatory clearance, global manufacturing depth, and a transformative radiopharma merger. The radioligand sector has resolved its regulatory question. The remaining battle is operational: proving who can deliver a decaying therapeutic to the clinic every eight weeks without failure.